Phase 2 Pancreatic Cancer Trial, Recruiting NCT06411795 Sponsor: Masonic Cancer Center, University of Minnesota Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT06411795
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who are having a specific type of pancreatic surgery (called open pancreaticoduodenectomy) at the University of Minnesota

Who may not be able to join:

  • People for whom a nerve-blocking procedure would be considered unsafe — for example, those with blood clotting problems, an allergy to local anaesthetic medicines, or an infection in the area where the block would be placed
  • People who have been regularly using opioid pain medicines (at a level of at least 30 morphine milligram equivalents per day) for three or more weeks before the surgery
  • People who may have difficulty understanding and completing a recovery questionnaire, as assessed at the discretion of the lead investigator or attending anaesthesiologist
  • People who have declined to take part or have previously opted out of research
  • People who are pregnant (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Masonic Cancer Center, University of Minnesota
Registry
ClinicalTrials.gov
Start date
10 November 2023
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Milligram morphine equivalents (MME)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov